Zevra Therapeutics, Inc.
NASDAQ:ZVRABiotechnology
+$0.31 today
- Market cap
- $552.20M
- Beta
- 0.89
- P/E (TTM)
- 6.1
- EPS (TTM)
- $2.13
Volume 0.62M
Average 1.43M
ZVRA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Zevra Therapeutics, Inc.NASDAQ: ZVRA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $4.39M rose 34.8% year over year, ahead of the -59.9% change in trailing-twelve-month research & development. Sequentially, it rose 67.6% from the prior quarter. Over 3 fiscal years it compounded at -13.7% a year.
Context
- Research & development amounted to 12.0% of revenue in FY2025, down 166.3 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +34.8% holds above the trailing-twelve-month pace of -59.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 12.74M USD
- Year-over-year change
- -69.7%
- 4-year CAGR
- +5.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.74M | -69.7% |
| FY2024 | 2024-12-31 | 42.1M | +5.8% |
| FY2023 | 2023-12-31 | 39.81M | +101.0% |
| FY2022 | 2022-12-31 | 19.8M | +94.9% |
| FY2021 | 2021-12-31 | 10.16M | — |
Research & Development vs competitors
How ZVRA compares with its peers on the latest reported figures
- ZVRA's LTM Mar 2026 research & development of $13.88M is the lowest of the 11 companies compared; the peer median is $230.54M.
- Its year-over-year change of -59.9% is the lowest of 11, against a peer median of +22.7%.
- Research & development amounts to 11.3% of revenue for ZVRA, versus a peer median of 19.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.23B | +30.7% | +29.9% | 33.3% | |
| LTM Sep 2026 | $623.61M | -26.8% | +9.9% | 13.2% | |
| LTM Sep 2026 | $430.42M | +49.7% | +5.9% | 24.5% | |
| LTM Sep 2026 | $371.08M | +36.1% | +41.7% | — | |
| LTM Sep 2026 | $289.11M | +17.6% | +19.9% | — | |
| LTM Mar 2026 | $171.97M | +136.8% | +73.1% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $162.51M | -21.6% | +18.9% | — |
| LTM Jun 2026 | $126.09M | +18.1% | +12.5% | 15.2% | |
| LTM Mar 2026 | $55.94M | +19.0% | +24.4% | — | |
| LTM Mar 2026 | $43.27M | +26.5% | +23.7% | — | |
| LTM Mar 2026 | $13.88M | -59.9% | -13.7% | 11.3% | |
| Peer median (excluding ZVRA) | $230.54M | +22.7% | +21.8% | 19.9% | |
Competitors are the stored peer set for ZVRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 28.65M | 10.16M | 27.46M | 23.61M | 106.47M |
| Cost of Revenue | 2.06M | 222K | 2.95M | 7.42M | 16.48M |
| Gross Profit | 26.59M | 9.94M | 24.52M | 16.2M | 89.99M |
| Gross Margin | 92.8% | 97.8% | 89.3% | 68.6% | 84.5% |
| Research & Development | 10.16M | 19.8M | 39.81M | 42.1M | 12.74M |
| Selling, General & Admin | 8.7M | 15.04M | 35.09M | 54.87M | 77.62M |
| Operating Expenses | 18.86M | 52.5M | 74.12M | 103.2M | 94.22M |
| Depreciation & Amortization | 257K | 944K | 1.01M | 6.39M | 4.05M |
| EBITDA | (7.89M) | (25.53M) | (43.54M) | (76.4M) | 98.71M |
| EBITDA Margin | -27.5% | -251.2% | -158.6% | -323.6% | 92.7% |
| Operating Income | 7.73M | (42.57M) | (49.6M) | (87M) | (4.23M) |
| Operating Margin | 27.0% | -418.9% | -180.6% | -368.5% | -4.0% |
| Interest Income | 261K | 1.51M | 4.54M | 2.18M | 6.95M |
| Interest Expense | 376K | 335K | 1.5M | 7.35M | 7.98M |
| Other Income / Expenses | (16.25M) | 15.76M | 3.56M | (3.14M) | 90.91M |
| Income Before Tax | (8.52M) | (26.81M) | (46.05M) | (90.14M) | 86.68M |
| Pre-Tax Margin | -29.7% | -263.8% | -167.7% | -381.8% | 81.4% |
| Income Tax Expense | 34K | (33K) | 0 | 15.37M | 3.45M |
| Net Income | (8.56M) | (26.77M) | (46.05M) | (105.51M) | 83.23M |
| Net Margin | -29.9% | -263.5% | -167.7% | -446.9% | 78.2% |
| EPS (Basic) | (2.11) | (0.78) | (1.30) | (2.28) | 1.40 |
| EPS (Diluted) | (2.11) | (0.78) | (1.30) | (2.28) | 1.35 |
| Weighted Avg Shares | 29.77M | 34.49M | 35.45M | 46.25M | 55.31M |
| Weighted Avg Shares (Diluted) | 29.77M | 34.49M | 35.45M | 46.25M | 57.26M |
Zevra Therapeutics, Inc.
NASDAQ:ZVRA
Intrinsic Alpha fair value
Locked
Current Price
$9.28
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.